Literature DB >> 18024827

Photodynamic therapy in non-subfoveal choroidal neovascularization secondary to pathological myopia: 1-year outcome.

Juan Reche-Frutos1, Cristina Calvo-González, Juan Donate-López, Julián García-Feijoó, M Wasfy, F Saenz-Frances, C Fernandez-Perez, J Garcia-Sanchez.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 18024827      PMCID： PMC2095513          DOI： 10.1136/bjo.2006.112045

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  4 in total

Review 1.  Myopic choroidal neovascularization: natural course and treatment.

Authors:  Kyoko Ohno-Matsui; Takeshi Yoshida
Journal:  Curr Opin Ophthalmol       Date:  2004-06       Impact factor: 3.761

2.  Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment.

Authors:  Ruth Axer-Siegel; Rita Ehrlich; Dov Weinberger; Irit Rosenblatt; Ludmila Shani; Yuval Yassur; Ethan Priel; Michal Kramer
Journal:  Am J Ophthalmol       Date:  2004-10       Impact factor: 5.258

3.  Characteristics of patients with a favorable natural course of myopic choroidal neovascularization.

Authors:  Kengo Hayashi; Kyoko Ohno-Matsui; Takeshi Yoshida; Kanako Kobayashi; Ariko Kojima; Noriaki Shimada; Kenjiro Yasuzumi; Soh Futagami; Takashi Tokoro; Manabu Mochizuki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-07-28       Impact factor: 3.117

4.  Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia-1-year results of a prospective series.

Authors:  D S C Lam; D T L Liu; D S P Fan; W W Lai; S F So; W-M Chan
Journal:  Eye (Lond)       Date:  2005-08       Impact factor: 3.775
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.